aiwiki.page
English
Health / Diseases & Symptoms / mast-cell-activation-syndrome

Mast Cell Activation Syndrome

Mast cell activation syndrome is characterized by recurrent systemic episodes of mast-cell mediator release, supported by objective laboratory findings and a response to mediator-directed treatment.

16 keywords3 linked from1 not yet writtenWritten by AI
Mast CellAnaphylaxisImmune SystemHistamineAllergyMastocytosisUrticariaAbdominal painMast Cell…

Mast cell activation syndrome (MCAS) is a disorder characterized by recurrent, acute episodes of symptoms caused by excessive release of chemical mediators from mast cells. Under widely used international consensus criteria, these episodes involve at least two organ systems, are accompanied by an objectively documented increase in mast-cell mediators, and improve with treatment directed against those mediators. Severe episodes can resemble or constitute anaphylaxis. MCAS is not established by nonspecific symptoms or an elevated baseline mediator level alone.

Biological basis

Mast cells are tissue-resident cells of the immune system, particularly abundant near blood vessels and at interfaces with the environment, including the skin, airways, and gastrointestinal tract. They participate in immediate allergic reactions and other immune responses.

When activated, mast cells release stored substances, including histamine and tryptase, and generate additional mediators such as prostaglandins and leukotrienes. These substances can increase vascular permeability, dilate blood vessels, constrict airways, and alter intestinal activity.

Mast-cell activation is a normal biological process and occurs in many conditions, including allergy. MCAS refers to a defined clinical syndrome of recurrent systemic activation, rather than to every instance of mast-cell activity. It also differs from mastocytosis, in which abnormal clonal mast cells accumulate in tissues. The two conditions can coexist.

Clinical features

Characteristic episodes involve combinations of symptoms affecting different organ systems:

  • Skin and mucous membranes: flushing, itching, hives, and swelling.
  • Cardiovascular system: rapid heartbeat, a fall in blood pressure, light-headedness, or collapse.
  • Respiratory system: wheezing, breathing difficulty, or upper-airway swelling.
  • Gastrointestinal tract: cramping abdominal pain, vomiting, and diarrhea.

The temporal pattern matters: several manifestations occur together during discrete attacks. Persistent fatigue, headache, gastrointestinal discomfort, or cognitive complaints are not specific enough to establish MCAS.

Episodes may follow exposure to an allergen or another identifiable trigger, but some have no apparent precipitant. Neither the number of reported triggers nor symptom severity alone determines whether diagnostic criteria are met.

Diagnostic criteria

The widely used consensus framework requires all three of the following components.

Recurrent systemic episodes

There must be recurrent, acute symptoms consistent with mast-cell mediator release, usually involving at least two organ systems. Localized symptoms alone, such as isolated hives or isolated nasal symptoms, do not meet this systemic criterion.

Objective evidence of mediator release

A transient rise in serum tryptase during an episode is the best-established laboratory marker. The commonly used threshold is:

Tevent>1.2Tbaseline+2 ng/mL,T_{\text{event}} > 1.2T_{\text{baseline}} + 2\ \text{ng/mL},

where TeventT_{\text{event}} is the episode-associated tryptase concentration and TbaselineT_{\text{baseline}} is the concentration outside the episode. This is often called the “20% plus 2” rule.

Event samples are generally obtained within approximately one to four hours after symptom onset. A baseline sample is obtained after recovery, at least 24 hours after complete resolution. Timing is important because circulating tryptase decreases after an episode.

Urinary histamine metabolites, leukotriene E4, and prostaglandin D2 metabolites can provide additional evidence. Their interpretation is less standardized, and they are not interchangeable with the validated tryptase criterion.

A normal baseline tryptase does not exclude episodic mast-cell activation. Conversely, persistently elevated baseline tryptase does not by itself establish MCAS. Baseline elevation can occur in mastocytosis, hereditary alpha-tryptasemia, and other conditions.

Response to mediator-directed treatment

Symptoms must improve with treatment that blocks mast-cell mediators or reduces their release or effects. Such a response supports the diagnosis only when the clinical and laboratory criteria are also satisfied. Improvement with an antihistamine alone is insufficient because these drugs also relieve symptoms in several other disorders.

Classification and related conditions

MCAS is commonly classified according to the underlying mechanism:

  • Primary or clonal MCAS: an abnormal mast-cell population is identified, often involving an activating mutation in the KIT gene. This category includes patients with systemic mastocytosis and some with clonal mast cells who do not meet full mastocytosis criteria.
  • Secondary MCAS: activation results from an identifiable process, most commonly an allergic reaction.
  • Idiopathic MCAS: the diagnostic criteria are met, but neither a clonal mast-cell disorder nor an identifiable secondary cause is found.

Clonal disease and allergy can occur together.

Hereditary alpha-tryptasemia is an inherited trait involving increased copy numbers of alpha-tryptase–encoding sequences in the TPSAB1 gene. It commonly raises baseline tryptase and can modify the risk or severity of mediator-related reactions, but it is not synonymous with MCAS.

Differential diagnosis

The differential diagnosis includes allergic disorders, chronic spontaneous urticaria, mastocytosis, recurrent anaphylaxis, and conditions that produce overlapping symptoms without systemic mast-cell activation. Endocrine disorders, gastrointestinal diseases, medication effects, and cardiovascular or autonomic disorders can cause flushing, diarrhea, palpitations, or fainting.

Clinical assessment therefore distinguishes evidence of mediator release from symptoms that merely resemble its effects. Anaphylaxis is a clinical emergency diagnosis; it does not require laboratory confirmation before treatment, and anaphylaxis without a measurable tryptase rise does not automatically establish or exclude MCAS.

Treatment and evidence limitations

Treatment addresses acute reactions, mediator-related symptoms, and any identifiable underlying condition. Epinephrine is the first-line treatment for anaphylaxis. Antihistamines, leukotriene-modifying drugs, and mast-cell stabilizing agents are used for selected mediator-related manifestations. Some patients with refractory disease receive other specialist-directed therapies.

The evidence supporting long-term treatment specifically for consensus-defined MCAS remains limited. Much of the literature consists of observational studies, case series, or evidence extrapolated from related allergic and mast-cell disorders. Treatment response is therefore clinically relevant but cannot replace objective diagnostic evidence.

Epidemiology and diagnostic boundaries

The population prevalence of MCAS has not been reliably established. Published estimates are difficult to compare because studies have used different definitions, referral populations, and laboratory requirements.

Broader symptom-based definitions have also appeared in the literature, but they are not equivalent to the international consensus framework. Persistent multisystem symptoms without documented mediator elevation do not, by themselves, establish consensus-defined MCAS. This distinction is important when interpreting research findings and assessing the risk of overdiagnosis.